Novogen (NASDAQ:KZIA) Stock Falls 1.3% – Here’s Why

Posted by Francis Steltz on Oct 14th, 2026

Novogen Limited (NASDAQ:KZIA – Get Free Report)’s share price traded down 1.3% during mid-day trading on Monday. The stock traded as low as $8.72 and last traded at $8.81. 66,815 shares were traded during trading, a decline of 75% from the average session volume of 263,089 shares. The stock had previously closed at $8.93.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $40.00 target price on shares of Novogen in a report on Thursday, September 10th. Canaccord Genuity Group began coverage on shares of Novogen in a research report on Thursday, August 13th. They set a “buy” rating and a $29.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a report on Friday, July 17th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $28.80.

View Our Latest Analysis on KZIA

Novogen Stock Down 15.5%

The firm has a fifty day simple moving average of $11.64 and a 200-day simple moving average of $11.99.

Novogen Company Profile

(Get Free Report)

Novogen Limited was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.

Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.

In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA.